Erik Berg is the founder of AM Pharma. AM Pharma has raised $176M in total funding. Latest round: Series C. Backed by LSP, Andera Partners, Forbion.
Erik van den Berg is the CEO of AM-Pharma, a clinical stage biopharmaceutical company developing a treatment for acute kidney injury (AKI). Under his leadership, the company secured significant funding rounds to advance its recombinant human Alkaline Phosphatase (recAP) therapeutic through pivotal Phase III trials.
Full founder directory · Investor directory · Company funding database · Fundraising library
The Startup Fundraising Platform
Raise funds for your startup
Find the right investors and get real replies — instantly, powered by AI.
Takes 30 seconds · No credit card · Cancel anytime
Slide-by-slide guide